Affinity-Guided Conjugation to Antibodies for Use in Positron Emission Tomography
The radionuclide copper-64 is widely used in combination with biomolecules, such as antibodies, for positron emission tomography (PET). Copper-64 is ideal for the imaging of biomolecules with long circulation times due to its relatively long half-life, and when conjugated to an antibody, specific ce...
Gespeichert in:
Veröffentlicht in: | Bioconjugate chemistry 2019-03, Vol.30 (3), p.881-887 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 887 |
---|---|
container_issue | 3 |
container_start_page | 881 |
container_title | Bioconjugate chemistry |
container_volume | 30 |
creator | Skovsgaard, Mikkel B Jeppesen, Troels E Mortensen, Michael R Nielsen, Carsten H Madsen, Jacob Kjaer, Andreas Gothelf, Kurt V |
description | The radionuclide copper-64 is widely used in combination with biomolecules, such as antibodies, for positron emission tomography (PET). Copper-64 is ideal for the imaging of biomolecules with long circulation times due to its relatively long half-life, and when conjugated to an antibody, specific cells can be targeted in vivo. Here, we have prepared a trastuzumab–chelator conjugate by using affinity-guided conjugation, in which an azide was attached to the antibody prior to a strain promoted azide–alkyne cycloaddition reaction with DBCO-PEG4-NOTA. The conjugate was benchmarked against a standard nonspecific labeled trastuzumab–NOTA conjugate. The conjugates were tested for incorporation of copper-64, stability in buffer and plasma, and tumor targeting in vivo using PET imaging of mice with xenograft tumors expressing HER2. Both conjugates showed good incorporation of copper-64 and a high stability with less than 10% degradation after 36 h. Furthermore, both conjugates showed accumulation at the tumor site with mean uptake of 7.2 ± 2.4%ID/g and 5.2 ± 1.3%ID/g after 40 h for the affinity-guided labeled trastuzumab and the nonspecific labeled trastuzumab, respectively. |
doi_str_mv | 10.1021/acs.bioconjchem.9b00013 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2186616891</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2186616891</sourcerecordid><originalsourceid>FETCH-LOGICAL-a385t-9a27d63fc01232b6d4fa2f1ab19adaba02d527ace3bfe16b087950a8d5f7591a3</originalsourceid><addsrcrecordid>eNqFkEFPwjAUgBujEUT_gi7x4mXY17KtOxKCaEKiJnBu2rWFErZiux3495aAxHjx1Hf43teXD6EHwEPABJ5FFYbSuso1m2qt62EpMcZAL1AfMoLTEQNyGWc8oikwTHroJoRNREpg5Br1KGa4AMB99Dk2xja23aezziqtkklUdivRWtckrUvGTWulU1aHxDifLINObJN8uGBbH4lpbUM4oAtXu5UXu_X-Fl0ZsQ367vQO0PJlupi8pvP32dtkPE8FZVmbloIUKqemwkAokbkaGUEMCAmlUEIKTFRGClFpKo2GXGJWlBkWTGWmyEoQdICejt6dd1-dDi2Pt1R6uxWNdl3gBFieQ85KiOjjH3TjOt_E6zghI6AkL_IsUsWRqrwLwWvDd97Wwu85YH6ozmN1_qs6P1WPm_cnfydrrc57P5kjQI_AwXD--z_tN_aCk_g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2241326765</pqid></control><display><type>article</type><title>Affinity-Guided Conjugation to Antibodies for Use in Positron Emission Tomography</title><source>ACS Publications</source><source>MEDLINE</source><creator>Skovsgaard, Mikkel B ; Jeppesen, Troels E ; Mortensen, Michael R ; Nielsen, Carsten H ; Madsen, Jacob ; Kjaer, Andreas ; Gothelf, Kurt V</creator><creatorcontrib>Skovsgaard, Mikkel B ; Jeppesen, Troels E ; Mortensen, Michael R ; Nielsen, Carsten H ; Madsen, Jacob ; Kjaer, Andreas ; Gothelf, Kurt V</creatorcontrib><description>The radionuclide copper-64 is widely used in combination with biomolecules, such as antibodies, for positron emission tomography (PET). Copper-64 is ideal for the imaging of biomolecules with long circulation times due to its relatively long half-life, and when conjugated to an antibody, specific cells can be targeted in vivo. Here, we have prepared a trastuzumab–chelator conjugate by using affinity-guided conjugation, in which an azide was attached to the antibody prior to a strain promoted azide–alkyne cycloaddition reaction with DBCO-PEG4-NOTA. The conjugate was benchmarked against a standard nonspecific labeled trastuzumab–NOTA conjugate. The conjugates were tested for incorporation of copper-64, stability in buffer and plasma, and tumor targeting in vivo using PET imaging of mice with xenograft tumors expressing HER2. Both conjugates showed good incorporation of copper-64 and a high stability with less than 10% degradation after 36 h. Furthermore, both conjugates showed accumulation at the tumor site with mean uptake of 7.2 ± 2.4%ID/g and 5.2 ± 1.3%ID/g after 40 h for the affinity-guided labeled trastuzumab and the nonspecific labeled trastuzumab, respectively.</description><identifier>ISSN: 1043-1802</identifier><identifier>EISSN: 1520-4812</identifier><identifier>DOI: 10.1021/acs.bioconjchem.9b00013</identifier><identifier>PMID: 30807110</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Affinity ; Alkynes ; Animals ; Antibodies ; Antibodies - administration & dosage ; Biomolecules ; Conjugates ; Conjugation ; Copper ; Cycloaddition ; ErbB-2 protein ; Humans ; Medical imaging ; Mice ; Monoclonal antibodies ; Positron emission ; Positron emission tomography ; Positron-Emission Tomography - methods ; Radioisotopes ; Stability ; Tomography ; Trastuzumab ; Trastuzumab - administration & dosage ; Tumors ; Xenografts ; Xenotransplantation</subject><ispartof>Bioconjugate chemistry, 2019-03, Vol.30 (3), p.881-887</ispartof><rights>Copyright American Chemical Society Mar 20, 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a385t-9a27d63fc01232b6d4fa2f1ab19adaba02d527ace3bfe16b087950a8d5f7591a3</citedby><cites>FETCH-LOGICAL-a385t-9a27d63fc01232b6d4fa2f1ab19adaba02d527ace3bfe16b087950a8d5f7591a3</cites><orcidid>0000-0003-0261-1385 ; 0000-0002-5009-4522 ; 0000-0003-2399-3757</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acs.bioconjchem.9b00013$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acs.bioconjchem.9b00013$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,776,780,2752,27053,27901,27902,56713,56763</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30807110$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Skovsgaard, Mikkel B</creatorcontrib><creatorcontrib>Jeppesen, Troels E</creatorcontrib><creatorcontrib>Mortensen, Michael R</creatorcontrib><creatorcontrib>Nielsen, Carsten H</creatorcontrib><creatorcontrib>Madsen, Jacob</creatorcontrib><creatorcontrib>Kjaer, Andreas</creatorcontrib><creatorcontrib>Gothelf, Kurt V</creatorcontrib><title>Affinity-Guided Conjugation to Antibodies for Use in Positron Emission Tomography</title><title>Bioconjugate chemistry</title><addtitle>Bioconjugate Chem</addtitle><description>The radionuclide copper-64 is widely used in combination with biomolecules, such as antibodies, for positron emission tomography (PET). Copper-64 is ideal for the imaging of biomolecules with long circulation times due to its relatively long half-life, and when conjugated to an antibody, specific cells can be targeted in vivo. Here, we have prepared a trastuzumab–chelator conjugate by using affinity-guided conjugation, in which an azide was attached to the antibody prior to a strain promoted azide–alkyne cycloaddition reaction with DBCO-PEG4-NOTA. The conjugate was benchmarked against a standard nonspecific labeled trastuzumab–NOTA conjugate. The conjugates were tested for incorporation of copper-64, stability in buffer and plasma, and tumor targeting in vivo using PET imaging of mice with xenograft tumors expressing HER2. Both conjugates showed good incorporation of copper-64 and a high stability with less than 10% degradation after 36 h. Furthermore, both conjugates showed accumulation at the tumor site with mean uptake of 7.2 ± 2.4%ID/g and 5.2 ± 1.3%ID/g after 40 h for the affinity-guided labeled trastuzumab and the nonspecific labeled trastuzumab, respectively.</description><subject>Affinity</subject><subject>Alkynes</subject><subject>Animals</subject><subject>Antibodies</subject><subject>Antibodies - administration & dosage</subject><subject>Biomolecules</subject><subject>Conjugates</subject><subject>Conjugation</subject><subject>Copper</subject><subject>Cycloaddition</subject><subject>ErbB-2 protein</subject><subject>Humans</subject><subject>Medical imaging</subject><subject>Mice</subject><subject>Monoclonal antibodies</subject><subject>Positron emission</subject><subject>Positron emission tomography</subject><subject>Positron-Emission Tomography - methods</subject><subject>Radioisotopes</subject><subject>Stability</subject><subject>Tomography</subject><subject>Trastuzumab</subject><subject>Trastuzumab - administration & dosage</subject><subject>Tumors</subject><subject>Xenografts</subject><subject>Xenotransplantation</subject><issn>1043-1802</issn><issn>1520-4812</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEFPwjAUgBujEUT_gi7x4mXY17KtOxKCaEKiJnBu2rWFErZiux3495aAxHjx1Hf43teXD6EHwEPABJ5FFYbSuso1m2qt62EpMcZAL1AfMoLTEQNyGWc8oikwTHroJoRNREpg5Br1KGa4AMB99Dk2xja23aezziqtkklUdivRWtckrUvGTWulU1aHxDifLINObJN8uGBbH4lpbUM4oAtXu5UXu_X-Fl0ZsQ367vQO0PJlupi8pvP32dtkPE8FZVmbloIUKqemwkAokbkaGUEMCAmlUEIKTFRGClFpKo2GXGJWlBkWTGWmyEoQdICejt6dd1-dDi2Pt1R6uxWNdl3gBFieQ85KiOjjH3TjOt_E6zghI6AkL_IsUsWRqrwLwWvDd97Wwu85YH6ozmN1_qs6P1WPm_cnfydrrc57P5kjQI_AwXD--z_tN_aCk_g</recordid><startdate>20190320</startdate><enddate>20190320</enddate><creator>Skovsgaard, Mikkel B</creator><creator>Jeppesen, Troels E</creator><creator>Mortensen, Michael R</creator><creator>Nielsen, Carsten H</creator><creator>Madsen, Jacob</creator><creator>Kjaer, Andreas</creator><creator>Gothelf, Kurt V</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0261-1385</orcidid><orcidid>https://orcid.org/0000-0002-5009-4522</orcidid><orcidid>https://orcid.org/0000-0003-2399-3757</orcidid></search><sort><creationdate>20190320</creationdate><title>Affinity-Guided Conjugation to Antibodies for Use in Positron Emission Tomography</title><author>Skovsgaard, Mikkel B ; Jeppesen, Troels E ; Mortensen, Michael R ; Nielsen, Carsten H ; Madsen, Jacob ; Kjaer, Andreas ; Gothelf, Kurt V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a385t-9a27d63fc01232b6d4fa2f1ab19adaba02d527ace3bfe16b087950a8d5f7591a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Affinity</topic><topic>Alkynes</topic><topic>Animals</topic><topic>Antibodies</topic><topic>Antibodies - administration & dosage</topic><topic>Biomolecules</topic><topic>Conjugates</topic><topic>Conjugation</topic><topic>Copper</topic><topic>Cycloaddition</topic><topic>ErbB-2 protein</topic><topic>Humans</topic><topic>Medical imaging</topic><topic>Mice</topic><topic>Monoclonal antibodies</topic><topic>Positron emission</topic><topic>Positron emission tomography</topic><topic>Positron-Emission Tomography - methods</topic><topic>Radioisotopes</topic><topic>Stability</topic><topic>Tomography</topic><topic>Trastuzumab</topic><topic>Trastuzumab - administration & dosage</topic><topic>Tumors</topic><topic>Xenografts</topic><topic>Xenotransplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Skovsgaard, Mikkel B</creatorcontrib><creatorcontrib>Jeppesen, Troels E</creatorcontrib><creatorcontrib>Mortensen, Michael R</creatorcontrib><creatorcontrib>Nielsen, Carsten H</creatorcontrib><creatorcontrib>Madsen, Jacob</creatorcontrib><creatorcontrib>Kjaer, Andreas</creatorcontrib><creatorcontrib>Gothelf, Kurt V</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Bioconjugate chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Skovsgaard, Mikkel B</au><au>Jeppesen, Troels E</au><au>Mortensen, Michael R</au><au>Nielsen, Carsten H</au><au>Madsen, Jacob</au><au>Kjaer, Andreas</au><au>Gothelf, Kurt V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Affinity-Guided Conjugation to Antibodies for Use in Positron Emission Tomography</atitle><jtitle>Bioconjugate chemistry</jtitle><addtitle>Bioconjugate Chem</addtitle><date>2019-03-20</date><risdate>2019</risdate><volume>30</volume><issue>3</issue><spage>881</spage><epage>887</epage><pages>881-887</pages><issn>1043-1802</issn><eissn>1520-4812</eissn><abstract>The radionuclide copper-64 is widely used in combination with biomolecules, such as antibodies, for positron emission tomography (PET). Copper-64 is ideal for the imaging of biomolecules with long circulation times due to its relatively long half-life, and when conjugated to an antibody, specific cells can be targeted in vivo. Here, we have prepared a trastuzumab–chelator conjugate by using affinity-guided conjugation, in which an azide was attached to the antibody prior to a strain promoted azide–alkyne cycloaddition reaction with DBCO-PEG4-NOTA. The conjugate was benchmarked against a standard nonspecific labeled trastuzumab–NOTA conjugate. The conjugates were tested for incorporation of copper-64, stability in buffer and plasma, and tumor targeting in vivo using PET imaging of mice with xenograft tumors expressing HER2. Both conjugates showed good incorporation of copper-64 and a high stability with less than 10% degradation after 36 h. Furthermore, both conjugates showed accumulation at the tumor site with mean uptake of 7.2 ± 2.4%ID/g and 5.2 ± 1.3%ID/g after 40 h for the affinity-guided labeled trastuzumab and the nonspecific labeled trastuzumab, respectively.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>30807110</pmid><doi>10.1021/acs.bioconjchem.9b00013</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-0261-1385</orcidid><orcidid>https://orcid.org/0000-0002-5009-4522</orcidid><orcidid>https://orcid.org/0000-0003-2399-3757</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1043-1802 |
ispartof | Bioconjugate chemistry, 2019-03, Vol.30 (3), p.881-887 |
issn | 1043-1802 1520-4812 |
language | eng |
recordid | cdi_proquest_miscellaneous_2186616891 |
source | ACS Publications; MEDLINE |
subjects | Affinity Alkynes Animals Antibodies Antibodies - administration & dosage Biomolecules Conjugates Conjugation Copper Cycloaddition ErbB-2 protein Humans Medical imaging Mice Monoclonal antibodies Positron emission Positron emission tomography Positron-Emission Tomography - methods Radioisotopes Stability Tomography Trastuzumab Trastuzumab - administration & dosage Tumors Xenografts Xenotransplantation |
title | Affinity-Guided Conjugation to Antibodies for Use in Positron Emission Tomography |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T00%3A52%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Affinity-Guided%20Conjugation%20to%20Antibodies%20for%20Use%20in%20Positron%20Emission%20Tomography&rft.jtitle=Bioconjugate%20chemistry&rft.au=Skovsgaard,%20Mikkel%20B&rft.date=2019-03-20&rft.volume=30&rft.issue=3&rft.spage=881&rft.epage=887&rft.pages=881-887&rft.issn=1043-1802&rft.eissn=1520-4812&rft_id=info:doi/10.1021/acs.bioconjchem.9b00013&rft_dat=%3Cproquest_cross%3E2186616891%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2241326765&rft_id=info:pmid/30807110&rfr_iscdi=true |